Want to see AU:M7T full AI Analyst Report?
M7T Stock Chart & Stats
AU$0.28
>-AU$0.01(-1.69%)
At close: 4:00 PM EDT
AU$0.28
>-AU$0.01(-1.69%)
Day’s Range― - ―
52-Week RangeAU$0.22 - AU$0.69
Previous CloseN/A
Volume106.68K
Average Volume (3M)109.51K
Market Cap
AU$54.05M
Enterprise ValueAU$48.31
Total Cash (Recent Filing)AU$19.92M
Total Debt (Recent Filing)AU$80.39K
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Mar 03, 2027EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding235,009,720
10 Day Avg. Volume146,137
30 Day Avg. Volume109,509
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)1.97
Price to Sales (P/S)2.44
P/FCF Ratio-51.12
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.40Price Target Upside42.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.03
Revenue Forecast (FY)AU$30.70M
Bulls Say, Bears Say
Bulls Say
Recurring Revenue BaseThe predominance of recurring revenue and contracted ARR gives Mach7 greater visibility than a purely license-led model. A predictable revenue base can support customer retention, implementation planning, and more durable cash generation as module adoption expands.
High Gross Margin And Cost DisciplineA 93% gross margin indicates strong software economics, while the 16% reduction in operating expenses creates a leaner cost structure. Together, these factors provide operating leverage potential if recurring revenue stabilizes and commercial investments produce sustained growth.
Debt-free Balance SheetCash of $19.9 million and no debt provide financial flexibility during the company’s restructuring and growth reset. This reduces refinancing pressure and preserves the capacity to fund product development, customer deployments, or selective strategic investment.
Bears Say
Weak Profitability And Revenue TrendThe sharp revenue decline and sizable net loss show that Mach7 has not yet converted its software model into sustainable earnings. Continued losses can restrict reinvestment and make future operating leverage dependent on a successful return to growth.
Negative Full-year Cash GenerationNegative annual operating and free cash flow indicates that reported software economics are not yet translating consistently into cash. Quarterly improvement is encouraging, but persistent cash burn would reduce the runway available for execution and strategic investment.
Customer Losses And Recurring Revenue PressureCustomer losses directly weaken contracted revenue and recurring growth, while also creating a higher hurdle for new bookings to offset churn. The impact on CAR and the revenue base makes retention, replacement wins, and deeper module adoption central to recovery.
Mach7 Technologies News
M7T FAQ
What was Mach7 Technologies Ltd.’s price range in the past 12 months?
Mach7 Technologies Ltd. lowest share price was AU$0.22 and its highest was AU$0.69 in the past 12 months.
What is Mach7 Technologies Ltd.’s market cap?
Mach7 Technologies Ltd.’s market cap is AU$54.05M.
When is Mach7 Technologies Ltd.’s upcoming earnings report date?
Mach7 Technologies Ltd.’s upcoming earnings report date is Mar 03, 2027 which is in 165 days.
How were Mach7 Technologies Ltd.’s earnings last quarter?
Mach7 Technologies Ltd. released its earnings results on Aug 27, 2026. The company reported -AU$0.012 earnings per share for the quarter.
Is Mach7 Technologies Ltd. overvalued?
According to Wall Street analysts Mach7 Technologies Ltd.’s price is currently Undervalued.
Does Mach7 Technologies Ltd. pay dividends?
Mach7 Technologies Ltd. does not currently pay dividends.
What is Mach7 Technologies Ltd.’s EPS estimate?
Mach7 Technologies Ltd.’s EPS estimate is -0.01.
How many shares outstanding does Mach7 Technologies Ltd. have?
Mach7 Technologies Ltd. has 235,009,720 shares outstanding.
What happened to Mach7 Technologies Ltd.’s price movement after its last earnings report?
Mach7 Technologies Ltd. reported an EPS of -AU$0.012 in its last earnings report. Following the earnings report the stock price went up 3.636%.
Which hedge fund is a major shareholder of Mach7 Technologies Ltd.?
Currently, no hedge funds are holding shares in AU:M7T
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mach7 Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-16.86%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Mach7 Technologies Ltd.
Mach7 Technologies Limited develops and commercializes medical imaging and data management software solutions for healthcare organizations in North America, the Asia Pacific, the Middle East, Europe, and internationally. It offers eUnity enterprise diagnostic viewer, a zero-footprint viewer that allows medical professionals to remotely access patients’ medical images; vendor-neutral archive (VNA), a vendor-agnostic data management solution, which includes administration tools that allow for the storage, access, retrieval, and viewing of images across a healthcare network. The company also provides workflow applications, such as a universal worklist, quality control (QC) tools designed for technologists’ workflows; image sharing and exchange capabilities; teleradiology services; and additional specialized tools to serve departmental patient care needs. Mach7 Technologies Limited was founded in 2007 and is headquartered in South Burlington, Vermont.
M7T Company Deck
M7T Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a cautious but constructive tone: FY'26 was framed as a deliberate reset that materially improved the business foundation—higher-quality recurring revenue mix, a 93% gross margin, reduced operating costs, a stronger leadership team, and clear second-half commercial momentum (ARR run rate +7.6% constant currency; H2 revenue +15% vs H1). However, meaningful near-term challenges remain including a 17% reported revenue decline, several sizable customer losses (notably VHA and Trinity Health), an $8.9M net loss, and FX-driven reporting headwinds. Management emphasized stabilization and a roadmap (Flamingo modules, Epic integrations, focused partnerships) to prove growth in FY'27. Overall, positives around margin, cash/no debt, cost discipline and H2 recovery modestly outweigh the lowlights, supporting cautious optimism.View all AU:M7T earnings summariesM7T Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
AU$0.40
▲(42.86% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Oneview Healthcare Chess Depository Interests repr 1
―
Pro Medicus Limited
―
Beamtree Holdings Ltd
―
Artrya Limited
―
Alcidion Group Limited
―







